284 related articles for article (PubMed ID: 17511984)
1. The Rho-kinase inhibitor, fasudil, attenuates diabetic nephropathy in streptozotocin-induced diabetic rats.
Gojo A; Utsunomiya K; Taniguchi K; Yokota T; Ishizawa S; Kanazawa Y; Kurata H; Tajima N
Eur J Pharmacol; 2007 Jul; 568(1-3):242-7. PubMed ID: 17511984
[TBL] [Abstract][Full Text] [Related]
2. Fasudil ameliorates endothelial dysfunction in streptozotocin-induced diabetic rats: a possible role of Rho kinase.
Hofni A; Shehata Messiha BA; Mangoura SA
Naunyn Schmiedebergs Arch Pharmacol; 2017 Aug; 390(8):801-811. PubMed ID: 28493050
[TBL] [Abstract][Full Text] [Related]
3. Involvement of the Rho/Rho kinase signaling pathway in platelet-derived growth factor BB-induced vascular endothelial growth factor expression in diabetic rat retina.
Yokota T; Utsunomiya K; Taniguchi K; Gojo A; Kurata H; Tajima N
Jpn J Ophthalmol; 2007; 51(6):424-30. PubMed ID: 18158592
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of Rho-kinase attenuates nephrosclerosis and improves survival in salt-loaded spontaneously hypertensive stroke-prone rats.
Nishikimi T; Koshikawa S; Ishikawa Y; Akimoto K; Inaba C; Ishimura K; Ono H; Matsuoka H
J Hypertens; 2007 May; 25(5):1053-63. PubMed ID: 17414670
[TBL] [Abstract][Full Text] [Related]
5. Fasudil, a Rho-kinase inhibitor, attenuates glomerulosclerosis in Dahl salt-sensitive rats.
Nishikimi T; Akimoto K; Wang X; Mori Y; Tadokoro K; Ishikawa Y; Shimokawa H; Ono H; Matsuoka H
J Hypertens; 2004 Sep; 22(9):1787-96. PubMed ID: 15311108
[TBL] [Abstract][Full Text] [Related]
6. A Rho-kinase inhibitor, fasudil, prevents development of diabetes and nephropathy in insulin-resistant diabetic rats.
Kikuchi Y; Yamada M; Imakiire T; Kushiyama T; Higashi K; Hyodo N; Yamamoto K; Oda T; Suzuki S; Miura S
J Endocrinol; 2007 Mar; 192(3):595-603. PubMed ID: 17332527
[TBL] [Abstract][Full Text] [Related]
7. [The expression of connective tissue growth factor in renal cortex of 5/6 nephrectomized rats and its modulation by fluvastatin].
Song GW; Li C; Zheng YC; Kong J; Sun B
Zhonghua Yi Xue Za Zhi; 2003 Aug; 83(16):1428-32. PubMed ID: 14521748
[TBL] [Abstract][Full Text] [Related]
8. Transforming growth factor-beta2 and connective tissue growth factor in proliferative vitreoretinal diseases: possible involvement of hyalocytes and therapeutic potential of Rho kinase inhibitor.
Kita T; Hata Y; Kano K; Miura M; Nakao S; Noda Y; Shimokawa H; Ishibashi T
Diabetes; 2007 Jan; 56(1):231-8. PubMed ID: 17192487
[TBL] [Abstract][Full Text] [Related]
9. Blocking VEGF/Caveolin-1 signaling contributes to renal protection of fasudil in streptozotocin-induced diabetic rats.
Jin J; Peng C; Wu SZ; Chen HM; Zhang BF
Acta Pharmacol Sin; 2015 Jul; 36(7):831-40. PubMed ID: 25937636
[TBL] [Abstract][Full Text] [Related]
10. Fasudil hydrochloride hydrate, a Rho-kinase inhibitor, ameliorates hepatic fibrosis in rats with type 2 diabetes.
Zhou H; Fang C; Zhang L; Deng Y; Wang M; Meng F
Chin Med J (Engl); 2014; 127(2):225-31. PubMed ID: 24438608
[TBL] [Abstract][Full Text] [Related]
11. Expression of serum and glucocorticoid-inducible kinase1 in diabetic rats and its modulation by fluvastatin.
Wang X; Luo C; Liu J; Zhang C; Wang Y; Zhu Z
J Huazhong Univ Sci Technolog Med Sci; 2005; 25(6):651-4. PubMed ID: 16696316
[TBL] [Abstract][Full Text] [Related]
12. Effect of fasudil on Rho-kinase and nephropathy in subtotally nephrectomized spontaneously hypertensive rats.
Kanda T; Wakino S; Hayashi K; Homma K; Ozawa Y; Saruta T
Kidney Int; 2003 Dec; 64(6):2009-19. PubMed ID: 14633123
[TBL] [Abstract][Full Text] [Related]
13. Long-term administration of rho-kinase inhibitor ameliorates renal damage in malignant hypertensive rats.
Ishikawa Y; Nishikimi T; Akimoto K; Ishimura K; Ono H; Matsuoka H
Hypertension; 2006 Jun; 47(6):1075-83. PubMed ID: 16636194
[TBL] [Abstract][Full Text] [Related]
14. Involvement of Rho-kinase in experimental vascular endothelial dysfunction.
Shah DI; Singh M
Mol Cell Biochem; 2006 Feb; 283(1-2):191-9. PubMed ID: 16444602
[TBL] [Abstract][Full Text] [Related]
15. Targeting of RhoA/ROCK signaling ameliorates progression of diabetic nephropathy independent of glucose control.
Kolavennu V; Zeng L; Peng H; Wang Y; Danesh FR
Diabetes; 2008 Mar; 57(3):714-23. PubMed ID: 18083785
[TBL] [Abstract][Full Text] [Related]
16. Lovastatin inhibits transforming growth factor-beta1 expression in diabetic rat glomeruli and cultured rat mesangial cells.
Kim SI; Han DC; Lee HB
J Am Soc Nephrol; 2000 Jan; 11(1):80-87. PubMed ID: 10616843
[TBL] [Abstract][Full Text] [Related]
17. The Rho kinase inhibitor, fasudil, ameliorates diabetes-induced cardiac dysfunction by improving calcium clearance and actin remodeling.
Lai D; Gao J; Bi X; He H; Shi X; Weng S; Chen Y; Yang Y; Ye Y; Fu G
J Mol Med (Berl); 2017 Feb; 95(2):155-165. PubMed ID: 27576917
[TBL] [Abstract][Full Text] [Related]
18. Rho kinase inhibition protects kidneys from diabetic nephropathy without reducing blood pressure.
Komers R; Oyama TT; Beard DR; Tikellis C; Xu B; Lotspeich DF; Anderson S
Kidney Int; 2011 Feb; 79(4):432-42. PubMed ID: 20962741
[TBL] [Abstract][Full Text] [Related]
19. The Rho-kinase inhibitor fasudil restores normal motor nerve conduction velocity in diabetic rats by assuring the proper localization of adhesion-related molecules in myelinating Schwann cells.
Kanazawa Y; Takahashi-Fujigasaki J; Ishizawa S; Takabayashi N; Ishibashi K; Matoba K; Kawanami D; Yokota T; Tajima N; Utsunomiya K
Exp Neurol; 2013 Sep; 247():438-46. PubMed ID: 23337773
[TBL] [Abstract][Full Text] [Related]
20. Targeting of Rho kinase ameliorates impairment of diabetic endothelial function in intrarenal artery.
Yin H; Ru H; Yu L; Kang Y; Lin G; Liu C; Sun L; Shi L; Sun Q; Liu C
Int J Mol Sci; 2013 Oct; 14(10):20282-98. PubMed ID: 24129169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
